Cargando…

No Differential Regulation of Dopamine Transporter (DAT) and Vesicular Monoamine Transporter 2 (VMAT2) Binding in a Primate Model of Parkinson Disease

Radioligands for DAT and VMAT2 are widely used presynaptic markers for assessing dopamine (DA) nerve terminals in Parkinson disease (PD). Previous in vivo imaging and postmortem studies suggest that these transporter sites may be regulated as the numbers of nigrostriatal neurons change in pathologic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, LinLin, Karimi, Morvarid, Loftin, Susan K., Brown, Chris A., Xia, HuChuan, Xu, JinBin, Mach, Robert H., Perlmutter, Joel S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281061/ https://www.ncbi.nlm.nih.gov/pubmed/22359591 http://dx.doi.org/10.1371/journal.pone.0031439

Ejemplares similares

Dopamine D(1), D(2), D(3) Receptors, Vesicular Monoamine Transporter Type-2 (VMAT2) and Dopamine Transporter (DAT) Densities in Aged Human Brain
por: Sun, Jianjun, et al.
Publicado: (2012)

Increased Vesicular Monoamine Transporter 2 (VMAT2) and Dopamine Transporter (DAT) Expression in Adolescent Brain Development: A Longitudinal Micro-PET/CT Study in Rodent
por: Jiang, Donglang, et al.
Publicado: (2019)

Vesicular monoamine transporter (VMAT) regional expression and roles in pathological conditions
por: Alwindi, Malik, et al.
Publicado: (2023)

Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas
por: Saisho, Yoshifumi, et al.
Publicado: (2008)

Functional genetic variants in the vesicular monoamine transporter 1 (VMAT1) modulate emotion processing
por: Lohoff, Falk W., et al.
Publicado: (2013)

Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population
por: Richards, Misty, et al.
Publicado: (2006)

The ins and outs of vesicular monoamine transporters
por: Yaffe, Dana, et al.
Publicado: (2018)

Vesicular monoamine transporter, type 2 (vmat2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas
por: Freeby, Matthew, et al.
Publicado: (2012)

Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease
por: Brighina, Laura, et al.
Publicado: (2013)

Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management
por: Sreeram, Venkatesh, et al.
Publicado: (2019)

Tyrosine Hydroxylase, Vesicular Monoamine Transporter and Dopamine Transporter mRNA Expression in Nigrostriatal Tissue of Rats with Pedunculopontine Neurotoxic Lesion
por: Blanco-Lezcano, Lisette, et al.
Publicado: (2018)

Dopamine and vesicular monoamine transport loss supports incidental Lewy body disease as preclinical idiopathic Parkinson
por: Pifl, Christian, et al.
Publicado: (2023)

Selective Knockout of the Vesicular Monoamine Transporter 2 (Vmat2) Gene in Calbindin2/Calretinin-Positive Neurons Results in Profound Changes in Behavior and Response to Drugs of Abuse
por: König, Niclas, et al.
Publicado: (2020)

Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors
por: Caroff, Stanley N.
Publicado: (2020)

An Acidic Motif Retains Vesicular Monoamine Transporter 2 on Large Dense Core Vesicles
por: Waites, Clarissa L., et al.
Publicado: (2001)

Insights to ligand binding to the monoamine transporters—from homology modeling to LeuBAT and dDAT
por: Koldsø, Heidi, et al.
Publicado: (2015)

Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters
por: Kölby, L, et al.
Publicado: (2003)

Preliminary Evidence of Apathetic-Like Behavior in Aged Vesicular Monoamine Transporter 2 Deficient Mice
por: Baumann, Aron, et al.
Publicado: (2016)

A Brief Review on the Role of Vesicular Monoamine Transporter(2) Inhibitors in Hyperkinetic Movement Disorders
por: NIKKHAH, Ali
Publicado: (2021)

Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients
por: Xu, San San, et al.
Publicado: (2018)

(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia
por: Wang, Wenyan, et al.
Publicado: (2021)

Brain Imaging of Vesicular Monoamine Transporter Type 2 in Healthy Aging Subjects by (18)F-FP-(+)-DTBZ PET
por: Lin, Kun-Ju, et al.
Publicado: (2013)

The Role of Dopamine and Dopaminergic Pathways in Dystonia: Insights from Neuroimaging
por: Karimi, Morvarid, et al.
Publicado: (2015)

Polymorphism in the Vesicular Monoamine Transporter 2 Gene Decreases the Risk of Parkinson's Disease in Han Chinese Men
por: Yang, Xinglong, et al.
Publicado: (2015)

A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2
por: Huang, Zih-Rou, et al.
Publicado: (2016)

Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism
por: Beauchamp, Leah C., et al.
Publicado: (2020)

Presence and Function of Dopamine Transporter (DAT) in Stallion Sperm: Dopamine Modulates Sperm Motility and Acrosomal Integrity
por: Urra, Javier A., et al.
Publicado: (2014)

Differential Localization of Vesicular Acetylcholine and Monoamine Transporters in PC12 Cells but Not CHO Cells
por: Liu, Yongjian, et al.
Publicado: (1997)

Living without DAT: Loss and compensation of the dopamine transporter gene in sauropsids (birds and reptiles)
por: Lovell, P. V., et al.
Publicado: (2015)

Methylation in the Promoter Region of the Dopamine Transporter DAT1 Gene in People Addicted to Nicotine
por: Chmielowiec, Jolanta, et al.
Publicado: (2022)

DNA Methylation of the Dopamine Transporter DAT1 Gene—Bliss Seekers in the Light of Epigenetics
por: Chmielowiec, Krzysztof, et al.
Publicado: (2023)

Focus on Human Monoamine Transporter Selectivity. New Human DAT and NET Models, Experimental Validation, and SERT Affinity Exploration
por: Ortore, Gabriella, et al.
Publicado: (2020)

Preclinical Efficacy of Novel Vesicular Monoamine Transporter 2 Inhibitors as Antagonists of d-Methamphetamine Self-Administration in Rats
por: Hiranita, Takato
Publicado: (2015)

Implications for Combination Therapy of Selective Monoamine Reuptake Inhibitors on Dopamine Transporters
por: Ahn, Hyomin, et al.
Publicado: (2023)

A Glial Variant of the Vesicular Monoamine Transporter Is Required To Store Histamine in the Drosophila Visual System
por: Romero-Calderón, Rafael, et al.
Publicado: (2008)

Preferential localization of a vesicular monoamine transporter to dense core vesicles in PC12 cells
Publicado: (1994)

The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density
por: VanNess, Sidney H, et al.
Publicado: (2005)

Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1)
por: Mill, Jonathan, et al.
Publicado: (2005)

Dopaminergic Control of Attentional Flexibility: Inhibition of Return is Associated with the Dopamine Transporter Gene (DAT1)
por: Colzato, Lorenza S., et al.
Publicado: (2010)

Thermostabilization and purification of the human dopamine transporter (hDAT) in an inhibitor and allosteric ligand bound conformation
por: Navratna, Vikas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b91qlqjdt2gl9nkaie51n5tcdj